Details for Patent: 9,549,926
✉ Email this page to a colleague
Which drugs does patent 9,549,926 protect, and when does it expire?
Patent 9,549,926 protects LETAIRIS and is included in one NDA.
This patent has thirty-four patent family members in twenty-four countries.
Summary for Patent: 9,549,926
Title: | Compositions and methods of treating pulmonary hypertension |
Abstract: | Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations. |
Inventor(s): | Belardinelli; Luiz (Palo Alto, CA), Gillies; Hunter Campbell (El Granada, CA), Liang; Faquan (San Francisco, CA), Shryock; John (East Palo Alto, CA), Yang; Suya (Palo Alto, CA) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Application Number: | 14/079,548 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,549,926 |
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 9,549,926
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead | LETAIRIS | ambrisentan | TABLET;ORAL | 022081-001 | Jun 15, 2007 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3 | ⤷ Try a Trial | |||
Gilead | LETAIRIS | ambrisentan | TABLET;ORAL | 022081-002 | Jun 15, 2007 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3 | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,549,926
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 083422 | ⤷ Try a Trial | |||
Australia | 2011315891 | ⤷ Try a Trial | |||
Australia | 2016204638 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |